Łukasz M. Boryń

TL;DR: STARR-seq identifies thousands of cell type–specific enhancers across a broad continuum of strengths, links differential gene expression to differences in enhancer activity, and creates a genome-wide quantitative enhancer map, revealing the highly complex regulation of transcription.

TL;DR: The results identify and validate WNT signalling as a driver and candidate biomarker of primary and acquired BET resistance in leukaemia, and implicate the rewiring of transcriptional programs as an important mechanism promoting resistance to BET inhibitors and, potentially, other chromatin-targeted therapies.

TL;DR: All episomal enhancer activity assays in mammalian cells are overcome by employing the ORI as core promoter and by inhibiting two IFN-I-inducing kinases, enabling genome-wide STARR-seq screens in human cells.

TL;DR: Thousands of functional enhancer sequences from three different Drosophila cell lines are computationally dissected and it is found that the enhancers display distinct cis-regulatory sequence signatures, which are predictive of the enhancer' cell type-specific or broad activities.

TL;DR: It is demonstrated that enhancer activation depends on cis-regulatory motif combinations that differ between cell types and can predict cell-type-specific ecdysone targeting, and is applicable to study signal-dependent enhancers for different pathways and across organisms.